Singapore markets close in 5 hours 17 minutes

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.55+0.21 (+2.93%)
At close: 04:00PM EDT
7.38 -0.17 (-2.32%)
After hours: 07:41PM EDT

Atea Pharmaceuticals, Inc.

125 Summer Street
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees64

Key executives

NameTitlePayExercisedYear born
Dr. Jean-Pierre Sommadossi Ph.D.Founder, Chairman, CEO & Pres981.5kN/A1956
Ms. Andrea J. Corcoran J.D.CFO, Exec. VP of Legal & Sec.653.39kN/A1962
Mr. John F. VavrickaChief Commercial Officer528.52kN/A1964
Dr. Janet M.J. Hammond M.D., Ph.D.Chief Devel. Officer723.59kN/A1960
Dr. Maria Arantxa Horga M.D.Chief Medical Officer605.98kN/A1968
Mr. Wayne Foster CPA, CPAExec. VP of Fin. & Chief Accounting OfficerN/AN/A1969
Ms. Jonae R. BarnesSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Ariyapadi N. KrishnarajVP of MarketingN/AN/AN/A
Mr. Adel Moussa Ph.D.Exec. VP of ChemistryN/AN/AN/A
Mr. Xiao-Jian Zhou Ph.D.Exec. VP of Early Stage Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corporate governance

Atea Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.